IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Fulton Bank N.A.

Fulton Bank N.A. lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.8% during the second quarter, Holdings Channel reports. The institutional investor owned 3,442 shares of the medical research company’s stock after selling 63 shares during the quarter. Fulton Bank N.A.’s holdings in IQVIA were worth $728,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Versant Capital Management Inc grew its stake in IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Rise Advisors LLC acquired a new position in IQVIA in the 1st quarter valued at approximately $31,000. Riverview Trust Co bought a new stake in IQVIA during the 1st quarter worth approximately $32,000. Covestor Ltd boosted its position in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares during the last quarter. Finally, Security National Bank bought a new position in IQVIA in the 4th quarter valued at $41,000. Institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on IQV. Argus raised IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Barclays lifted their price target on shares of IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a research report on Tuesday, July 23rd. Evercore ISI lifted their price target on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group downgraded shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, UBS Group boosted their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $265.67.

IQVIA Stock Performance

Shares of IQV stock traded down $5.99 during trading hours on Wednesday, hitting $231.27. 677,371 shares of the company were exchanged, compared to its average volume of 1,089,367. The firm has a fifty day simple moving average of $222.06 and a 200 day simple moving average of $230.93. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market capitalization of $42.16 billion, a price-to-earnings ratio of 32.41, a P/E/G ratio of 2.28 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue was up 2.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.22 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.21 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.